Effect of one time high dose “stoss therapy” of vitamin D on glucose homeostasis in high risk obese adolescents

ABSTRACT Objective To study the effect of using a one time high dose “stoss therapy” of vitamin D2 (ergocalciferol: VD2) on indices of insulin sensitivity {whole body sensitivity index: WBISI} and secretion {insulinogenic index: IGI} measured during an oral glucose tolerance test (OGTT) in obese ado...

Full description

Saved in:
Bibliographic Details
Published in:Archives of Endocrinology and Metabolism 2018-03, Vol.62 (2), p.193-200
Main Authors: Brar, Preneet Cheema, Contreras, Maria, Fan, Xiaozhou, Visavachaipan, Nipapat
Format: Article
Language:English
Subjects:
insulin resistance
obesity
Original
prediabetes
Vitamin D
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c511t-640af729614781f4796c24c4a4dc68cc90d2f581641873e5bd99b4e3fe5cc1f53
cites cdi_FETCH-LOGICAL-c511t-640af729614781f4796c24c4a4dc68cc90d2f581641873e5bd99b4e3fe5cc1f53
container_end_page 200
container_issue 2
container_start_page 193
container_title Archives of Endocrinology and Metabolism
container_volume 62
creator Brar, Preneet Cheema
Contreras, Maria
Fan, Xiaozhou
Visavachaipan, Nipapat
description ABSTRACT Objective To study the effect of using a one time high dose “stoss therapy” of vitamin D2 (ergocalciferol: VD2) on indices of insulin sensitivity {whole body sensitivity index: WBISI} and secretion {insulinogenic index: IGI} measured during an oral glucose tolerance test (OGTT) in obese adolescents with VDD (25 OHD; serum metabolite of vit D: < 30 ng/dL). Subjects and methods In a randomized placebo controlled cross over design 20 obese adolescents with vitamin D deficiency (VDD) had baseline OGTT. Arm A received one time high dose 300,000 IU of ergocalciferol and Arm B received placebo. After 6 weeks the adolescents were reassigned to Arm A if they were in Arm B and vice versa. 25OHD, calcium, parathyroid hormone, comprehensive metabolic panel, urine calcium creatinine ratio were measured at each study visit. OGTTs to assess indices of sensitivity and secretion were done at baseline, 6 weeks and 12 weeks respectively. Results Adolescents were obese and insulin resistant (mean ± SD: mean age = 15.1 ± 1.9 years; BMI: 32.7 ± 9.8; homeostatic model of insulin resistance: HOMA-IR: 4.2 ± 2.8). Stoss therapy with VD2 increased 25OHD from baseline (16.7 ± 2.9 to 19.5 ± 4.5; p = 0.0029) when compared to the placebo. WBISI (2.8 ± 1.9) showed a trend towards improvement in Rx group (p = 0.0577) after adjustment for covariates. IGI (3 ± 2.2) showed an improvement in both Rx and placebo groups. Conclusions Our study demonstrated that using a high dose of VD2 (300,000 IU) did not have any beneficial effect on insulin sensitivity (whole body sensitivity index {WBISI}) and secretory indices (insulinogenic index {IGI}) in obese adolescents. High dose “stoss therapy” of VD2 did not appear to have any beneficial effect on glucose homeostasis on obese adolescents.
doi_str_mv 10.20945/2359-3997000000024
format article
fullrecord <record><control><sourceid>pubmedcentral_doaj_</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10118987</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_59de34ea00a4497bae2253d09cf9bcfc</doaj_id><sourcerecordid>pubmedcentral_primary_oai_pubmedcentral_nih_gov_10118987</sourcerecordid><originalsourceid>FETCH-LOGICAL-c511t-640af729614781f4796c24c4a4dc68cc90d2f581641873e5bd99b4e3fe5cc1f53</originalsourceid><addsrcrecordid>eNpVkU1OIzEQha0RowGFnGA2vkAG_6bbqxHiX0JiA2vLbZfTznTHkW2Q2HGQ4XKcBHeCkOKNrXqvPlX5IfSbkj-MKCHPGJdqwZVqyP4w8QOd7IqCKXb09Z4Mx2ie87paqKSUCvkLHTO1FLThzQnKV96DLTh6HDeASxgB92HVYxcz4I-3_7nEnHHpIZnt68fb--R8CcWMYYMvaw9eDc928vZxhJiLySHjqu0gKeR_OHZQZePiANnCpuRT9NObIcP8656hp-urx4vbxf3Dzd3F-f3C1kHLYimI8U0dlYqmpV40ammZsMIIZ5ettYo45mVL6yptw0F2TqlOAPcgraVe8hm623NdNGu9TWE06VVHE_SuENNKm1SCHUBL5YALMIQYIVTTGWBMckeU9aqz3lbW3z1r-9yN4KY9khkOoIfKJvR6FV80JZS2qg44Q3xPsKn-aAL_3UyJ3mWqp8j0Qab8Exn_lkI</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Effect of one time high dose “stoss therapy” of vitamin D on glucose homeostasis in high risk obese adolescents</title><source>SciELO Brazil</source><source>PubMed Central</source><creator>Brar, Preneet Cheema ; Contreras, Maria ; Fan, Xiaozhou ; Visavachaipan, Nipapat</creator><creatorcontrib>Brar, Preneet Cheema ; Contreras, Maria ; Fan, Xiaozhou ; Visavachaipan, Nipapat</creatorcontrib><description>ABSTRACT Objective To study the effect of using a one time high dose “stoss therapy” of vitamin D2 (ergocalciferol: VD2) on indices of insulin sensitivity {whole body sensitivity index: WBISI} and secretion {insulinogenic index: IGI} measured during an oral glucose tolerance test (OGTT) in obese adolescents with VDD (25 OHD; serum metabolite of vit D: &lt; 30 ng/dL). Subjects and methods In a randomized placebo controlled cross over design 20 obese adolescents with vitamin D deficiency (VDD) had baseline OGTT. Arm A received one time high dose 300,000 IU of ergocalciferol and Arm B received placebo. After 6 weeks the adolescents were reassigned to Arm A if they were in Arm B and vice versa. 25OHD, calcium, parathyroid hormone, comprehensive metabolic panel, urine calcium creatinine ratio were measured at each study visit. OGTTs to assess indices of sensitivity and secretion were done at baseline, 6 weeks and 12 weeks respectively. Results Adolescents were obese and insulin resistant (mean ± SD: mean age = 15.1 ± 1.9 years; BMI: 32.7 ± 9.8; homeostatic model of insulin resistance: HOMA-IR: 4.2 ± 2.8). Stoss therapy with VD2 increased 25OHD from baseline (16.7 ± 2.9 to 19.5 ± 4.5; p = 0.0029) when compared to the placebo. WBISI (2.8 ± 1.9) showed a trend towards improvement in Rx group (p = 0.0577) after adjustment for covariates. IGI (3 ± 2.2) showed an improvement in both Rx and placebo groups. Conclusions Our study demonstrated that using a high dose of VD2 (300,000 IU) did not have any beneficial effect on insulin sensitivity (whole body sensitivity index {WBISI}) and secretory indices (insulinogenic index {IGI}) in obese adolescents. High dose “stoss therapy” of VD2 did not appear to have any beneficial effect on glucose homeostasis on obese adolescents.</description><identifier>ISSN: 2359-3997</identifier><identifier>ISSN: 2359-4292</identifier><identifier>EISSN: 2359-4292</identifier><identifier>DOI: 10.20945/2359-3997000000024</identifier><identifier>PMID: 29641737</identifier><language>eng</language><publisher>Sociedade Brasileira de Endocrinologia e Metabologia</publisher><subject>insulin resistance ; obesity ; Original ; prediabetes ; Vitamin D</subject><ispartof>Archives of Endocrinology and Metabolism, 2018-03, Vol.62 (2), p.193-200</ispartof><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c511t-640af729614781f4796c24c4a4dc68cc90d2f581641873e5bd99b4e3fe5cc1f53</citedby><cites>FETCH-LOGICAL-c511t-640af729614781f4796c24c4a4dc68cc90d2f581641873e5bd99b4e3fe5cc1f53</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10118987/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10118987/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,315,733,786,790,891,27957,27958,53827,53829</link.rule.ids></links><search><creatorcontrib>Brar, Preneet Cheema</creatorcontrib><creatorcontrib>Contreras, Maria</creatorcontrib><creatorcontrib>Fan, Xiaozhou</creatorcontrib><creatorcontrib>Visavachaipan, Nipapat</creatorcontrib><title>Effect of one time high dose “stoss therapy” of vitamin D on glucose homeostasis in high risk obese adolescents</title><title>Archives of Endocrinology and Metabolism</title><description>ABSTRACT Objective To study the effect of using a one time high dose “stoss therapy” of vitamin D2 (ergocalciferol: VD2) on indices of insulin sensitivity {whole body sensitivity index: WBISI} and secretion {insulinogenic index: IGI} measured during an oral glucose tolerance test (OGTT) in obese adolescents with VDD (25 OHD; serum metabolite of vit D: &lt; 30 ng/dL). Subjects and methods In a randomized placebo controlled cross over design 20 obese adolescents with vitamin D deficiency (VDD) had baseline OGTT. Arm A received one time high dose 300,000 IU of ergocalciferol and Arm B received placebo. After 6 weeks the adolescents were reassigned to Arm A if they were in Arm B and vice versa. 25OHD, calcium, parathyroid hormone, comprehensive metabolic panel, urine calcium creatinine ratio were measured at each study visit. OGTTs to assess indices of sensitivity and secretion were done at baseline, 6 weeks and 12 weeks respectively. Results Adolescents were obese and insulin resistant (mean ± SD: mean age = 15.1 ± 1.9 years; BMI: 32.7 ± 9.8; homeostatic model of insulin resistance: HOMA-IR: 4.2 ± 2.8). Stoss therapy with VD2 increased 25OHD from baseline (16.7 ± 2.9 to 19.5 ± 4.5; p = 0.0029) when compared to the placebo. WBISI (2.8 ± 1.9) showed a trend towards improvement in Rx group (p = 0.0577) after adjustment for covariates. IGI (3 ± 2.2) showed an improvement in both Rx and placebo groups. Conclusions Our study demonstrated that using a high dose of VD2 (300,000 IU) did not have any beneficial effect on insulin sensitivity (whole body sensitivity index {WBISI}) and secretory indices (insulinogenic index {IGI}) in obese adolescents. High dose “stoss therapy” of VD2 did not appear to have any beneficial effect on glucose homeostasis on obese adolescents.</description><subject>insulin resistance</subject><subject>obesity</subject><subject>Original</subject><subject>prediabetes</subject><subject>Vitamin D</subject><issn>2359-3997</issn><issn>2359-4292</issn><issn>2359-4292</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNpVkU1OIzEQha0RowGFnGA2vkAG_6bbqxHiX0JiA2vLbZfTznTHkW2Q2HGQ4XKcBHeCkOKNrXqvPlX5IfSbkj-MKCHPGJdqwZVqyP4w8QOd7IqCKXb09Z4Mx2ie87paqKSUCvkLHTO1FLThzQnKV96DLTh6HDeASxgB92HVYxcz4I-3_7nEnHHpIZnt68fb--R8CcWMYYMvaw9eDc928vZxhJiLySHjqu0gKeR_OHZQZePiANnCpuRT9NObIcP8656hp-urx4vbxf3Dzd3F-f3C1kHLYimI8U0dlYqmpV40ammZsMIIZ5ettYo45mVL6yptw0F2TqlOAPcgraVe8hm623NdNGu9TWE06VVHE_SuENNKm1SCHUBL5YALMIQYIVTTGWBMckeU9aqz3lbW3z1r-9yN4KY9khkOoIfKJvR6FV80JZS2qg44Q3xPsKn-aAL_3UyJ3mWqp8j0Qab8Exn_lkI</recordid><startdate>20180301</startdate><enddate>20180301</enddate><creator>Brar, Preneet Cheema</creator><creator>Contreras, Maria</creator><creator>Fan, Xiaozhou</creator><creator>Visavachaipan, Nipapat</creator><general>Sociedade Brasileira de Endocrinologia e Metabologia</general><general>Brazilian Society of Endocrinology and Metabolism</general><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20180301</creationdate><title>Effect of one time high dose “stoss therapy” of vitamin D on glucose homeostasis in high risk obese adolescents</title><author>Brar, Preneet Cheema ; Contreras, Maria ; Fan, Xiaozhou ; Visavachaipan, Nipapat</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c511t-640af729614781f4796c24c4a4dc68cc90d2f581641873e5bd99b4e3fe5cc1f53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>insulin resistance</topic><topic>obesity</topic><topic>Original</topic><topic>prediabetes</topic><topic>Vitamin D</topic><toplevel>online_resources</toplevel><creatorcontrib>Brar, Preneet Cheema</creatorcontrib><creatorcontrib>Contreras, Maria</creatorcontrib><creatorcontrib>Fan, Xiaozhou</creatorcontrib><creatorcontrib>Visavachaipan, Nipapat</creatorcontrib><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Archives of Endocrinology and Metabolism</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Brar, Preneet Cheema</au><au>Contreras, Maria</au><au>Fan, Xiaozhou</au><au>Visavachaipan, Nipapat</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effect of one time high dose “stoss therapy” of vitamin D on glucose homeostasis in high risk obese adolescents</atitle><jtitle>Archives of Endocrinology and Metabolism</jtitle><date>2018-03-01</date><risdate>2018</risdate><volume>62</volume><issue>2</issue><spage>193</spage><epage>200</epage><pages>193-200</pages><issn>2359-3997</issn><issn>2359-4292</issn><eissn>2359-4292</eissn><notes>Disclosure: no potential conflict of interest relevant to this article was reported.</notes><abstract>ABSTRACT Objective To study the effect of using a one time high dose “stoss therapy” of vitamin D2 (ergocalciferol: VD2) on indices of insulin sensitivity {whole body sensitivity index: WBISI} and secretion {insulinogenic index: IGI} measured during an oral glucose tolerance test (OGTT) in obese adolescents with VDD (25 OHD; serum metabolite of vit D: &lt; 30 ng/dL). Subjects and methods In a randomized placebo controlled cross over design 20 obese adolescents with vitamin D deficiency (VDD) had baseline OGTT. Arm A received one time high dose 300,000 IU of ergocalciferol and Arm B received placebo. After 6 weeks the adolescents were reassigned to Arm A if they were in Arm B and vice versa. 25OHD, calcium, parathyroid hormone, comprehensive metabolic panel, urine calcium creatinine ratio were measured at each study visit. OGTTs to assess indices of sensitivity and secretion were done at baseline, 6 weeks and 12 weeks respectively. Results Adolescents were obese and insulin resistant (mean ± SD: mean age = 15.1 ± 1.9 years; BMI: 32.7 ± 9.8; homeostatic model of insulin resistance: HOMA-IR: 4.2 ± 2.8). Stoss therapy with VD2 increased 25OHD from baseline (16.7 ± 2.9 to 19.5 ± 4.5; p = 0.0029) when compared to the placebo. WBISI (2.8 ± 1.9) showed a trend towards improvement in Rx group (p = 0.0577) after adjustment for covariates. IGI (3 ± 2.2) showed an improvement in both Rx and placebo groups. Conclusions Our study demonstrated that using a high dose of VD2 (300,000 IU) did not have any beneficial effect on insulin sensitivity (whole body sensitivity index {WBISI}) and secretory indices (insulinogenic index {IGI}) in obese adolescents. High dose “stoss therapy” of VD2 did not appear to have any beneficial effect on glucose homeostasis on obese adolescents.</abstract><pub>Sociedade Brasileira de Endocrinologia e Metabologia</pub><pmid>29641737</pmid><doi>10.20945/2359-3997000000024</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2359-3997
ispartof Archives of Endocrinology and Metabolism, 2018-03, Vol.62 (2), p.193-200
issn 2359-3997
2359-4292
2359-4292
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10118987
source SciELO Brazil; PubMed Central
subjects insulin resistance
obesity
Original
prediabetes
Vitamin D
title Effect of one time high dose “stoss therapy” of vitamin D on glucose homeostasis in high risk obese adolescents
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-09-22T19%3A28%3A25IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmedcentral_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effect%20of%20one%20time%20high%20dose%20%E2%80%9Cstoss%20therapy%E2%80%9D%20of%20vitamin%20D%20on%20glucose%20homeostasis%20in%20high%20risk%20obese%20adolescents&rft.jtitle=Archives%20of%20Endocrinology%20and%20Metabolism&rft.au=Brar,%20Preneet%20Cheema&rft.date=2018-03-01&rft.volume=62&rft.issue=2&rft.spage=193&rft.epage=200&rft.pages=193-200&rft.issn=2359-3997&rft.eissn=2359-4292&rft_id=info:doi/10.20945/2359-3997000000024&rft_dat=%3Cpubmedcentral_doaj_%3Epubmedcentral_primary_oai_pubmedcentral_nih_gov_10118987%3C/pubmedcentral_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c511t-640af729614781f4796c24c4a4dc68cc90d2f581641873e5bd99b4e3fe5cc1f53%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/29641737&rfr_iscdi=true